When semaglutide dosing begins, your provider will almost always start at the lowest available dose (0.25 mg for weekly injections, or 3 mg for oral formulations)
[12] People with Crohn's disease, especially those with ileal involvement, may already have a higher baseline risk of gallstone formation [21] [22] Dehydration and acute kidney injury : Persistent vomiting or diarrhoea can lead to dehydration, particularly in vulnerable patients Bowel obstruction : For individuals with Crohn's disease, especially those with known strictures, the risk of obstruction may theoretically be increased due to the medication's effect on gastrointestinal motility Practical strategies to minimise side effects include: Starting with a low dose and gradually increasing as tolerated Eating smaller, lower-fat meals and avoiding overeating Maintaining adequate hydration Temporarily pausing dose escalation if symptoms become intolerable Patients should be advised to contact their GP or specialist immediately if they experience: Severe, persistent abdominal pain (especially if radiating to the back) Persistent vomiting preventing adequate fluid intake Signs of dehydration Blood in stools or black, tarry stools Symptoms suggesting bowel obstruction (severe cramping, inability to pass stool or gas, abdominal distension) Suspected adverse reactions should be reported via the Yellow Card Scheme (yellowcard.mhra.gov.uk or the Yellow Card app)
At 5 mg/mL, notice that a 0.25 mg dose is only 5 units
Summary: Sleep disturbances on Mounjaro are not officially listed as common adverse effects, but may occur due to gastrointestinal side effects, lifestyle changes, or other factors rather than direct medication action
Semaglutide should be completely clear and colorless
But many people experience weight reduction as a secondary effect
